Clinical trials: Sadness
Healthy, Osteoarthritis
Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation
This is a first in human, randomized, double-blind, placebo-controlled SAD (with food effect) followed by a MAD study of Trichomylin® conducted in healthy adult participants.
- Trial name
- HOPE (NCT04867057)
- Testing
- Trichomylin for SAD, Trichomylin for MAD
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- ZYUS Life Sciences Inc.
Healthy Volunteers
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
The objective of this study is to assess the safety, tolerability, pharmacokinetics and immunogenicity of either single ascending intravenous (IV) doses of ABBV-243 or single ascending subcutaneous (SC) doses of ABBV-243 in…
- Trial name
- NCT07306754
- Testing
- ABBV-243
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- AbbVie
Social Anxiety Disorder, Body Dysmorphic Disorder
Individual Factors of CBT Underlying Success
The purpose of this study is to understand why some individuals respond fully to cognitive behavioral therapy and others do not, based on multiple sources of data such as neural, neurocognitive, clinical, and self-report data.
- Trial name
- I-FOCUS (NCT06678295)
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University of Washington
Major Depressive Disorder
Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression
The Purposes of this Study are to determine: The safety of duloxetine and any side effects that might be associated with it. Whether duloxetine can help patients with major depression.
- Trial name
- NCT00042575
- Testing
- Duloxetine
- Where
- 9 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Systemic Lupos Erythematosus, SLE
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants
The primary objective of the study is to evaluate the safety and tolerability of single oral doses of BIIB068 in healthy participants.
- Trial name
- NCT02829541
- Testing
- BIIB068
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biogen
Normal Healthy Subjects
Study to Evaluate HT-4253 in Healthy Subjects
The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects.
- Trial name
- NCT06537817
- Testing
- HT-4253
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Halia Therapeutics, Inc.
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
This is a 6-part first-in-human study in up to approximately 184 participants. Parts 1 to 5 is in health volunteers and part 6 is in subjects with atopic dermatitis.
- Trial name
- NCT03918980
- Testing
- LOU064
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hyperuricemia
A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
This research study is studying an investigational drug called FCN-207 in healthy adult males or females.
- Trial name
- NCT04622124
- Testing
- fasted vs. high-fat meal
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Inflammatory Bowel Disease, Colitis, Ulcerative
LMT503 First-in-human SAD, MAD, and FE Study
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT05659953
- Testing
- LMT503
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lmito Therapeutics Inc.
Major Depressive Disorder, Healthy Volunteer
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
- Trial name
- NCT07334249
- Testing
- SP-101 injection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.
Major Depressive Disorder
Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration.
- Trial name
- NCT04711005
- Testing
- (2R,6R)-Hydroxynorketamine hydrochloride
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Asthma
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898
In this integrated, multi-part, Phase I study, the safety, tolerability, food effect, pharmacokinetic (PK) and pharmacodynamic (PD) properties of single and repeated doses of AZD9898 will be investigated.
- Trial name
- NCT03140072
- Testing
- AZD9898
- Where
- 2 sites in United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Huntington Disease
CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects
To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and Caucasian adult subjects
- Trial name
- NCT03713892
- Testing
- CKD-504
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
COVID-19
SAD Study of APR002 Investigating the Safety/Tolerability, Pharmacokinetics/Pharmacodynamics in Healthy Subjects
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of APR002 in healthy subjects.
- Trial name
- NCT05268198
- Testing
- APR002
- Where
- Australia
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Global Health Drug Discovery Institute
Nonalcoholic Steatohepatitis (NASH)
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
This study will consist of 3 parts: Part A - Single Ascending Dose (SAD) phase, Part B - multiple ascending dose (MAD) phase, and Part C - Food Effect (FE) phase.
- Trial name
- NCT04913090
- Testing
- XZP-5610 Tablet (for Part A), XZP-5610 Tablet (for Part B), XZP-5610 Tablet （for "Part C1"）
- Where
- China
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Xuanzhu Biopharmaceutical Co., Ltd.
Anxiety Disorder/Anxiety State
Online Acceptance and Commitment Therapy for Reducing Anxiety
The main objective of this study is to test the effectiveness of an Internet-delivered Acceptance and Commitment Therapy (ACT) program in reducing anxiety symptoms.
- Trial name
- NCT03074669
- Testing
- ACT program
- Where
- Romania
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- West University of Timisoara
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Healthy Subjects
The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects
This is a phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of single ascending doses and multiple ascending doses of SYHX1901 tablets in Chinese healthy subjects
- Trial name
- NCT04880512
- Testing
- SYHX 1901 tablets
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Healthy Volunteers
First-in-human Study of MRT-6160 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when MRT-6160 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT06597799
- Testing
- MRT-6160
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Monte Rosa Therapeutics, Inc